Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 8:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Bimatoprost Solution 2 Clear all
Completed Phase 4 Interventional Results available

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

NCT01170884
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 11, 2026, 8:31 AM EDT
Completed Phase 2 Interventional Results available

Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension

NCT01915940
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost, Timolol 0.5%, Placebo Eye Drops, Placebo Ocular Insert
Drug · Device
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Artesia, California • La Jolla, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2018 · Synced Sep 11, 2026, 8:31 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

NCT00652496
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Bimatoprost 0.01% ophthalmic solution, Bimatoprost 0.015% formulation 1 ophthalmic solution, Bimatoprost 0.015% formulation 2 ophthalmic solution, Bimatoprost 0.02% ophthalmic solution, Bimatoprost 0.03% ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Wenatchee, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Sep 11, 2026, 8:31 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

NCT04499248
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AGN-193408 SR, Lumigan, Sham Administration, Lumigan Vehicle
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
42
States / cities
Sun City, Arizona • Glendale, California • Inglewood, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 11, 2026, 8:31 AM EDT
Completed Phase 3 Interventional

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma

NCT04890106
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
Drug
Lead sponsor
Mankind Pharma Limited
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Bakersfield, California • Mission Hills, California • Newport Beach, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 11, 2026, 8:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure

NCT02448043
View directory record Official record
Conditions
Nail Growth Cessation, Intraocular Pressure
Interventions
Bimatoprost 0.01%, Placebo: saline
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Sep 11, 2026, 8:31 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

NCT01904721
View directory record Official record
Conditions
Alopecia, Alopecia, Androgenetic, Baldness
Interventions
Bimatoprost Solution 1, Bimatoprost Solution 2, Bimatoprost Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Fridley, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 11, 2026, 8:31 AM EDT
Not listed Phase 1 Interventional

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

NCT06267274
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost Ophthalmic Solution, 0.01%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Bakersfield, California • Newport Beach, California • Morrow, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 11, 2026, 8:31 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT01110499
View directory record Official record
Conditions
Ocular Hypertension, Primary Open-Angle Glaucoma
Interventions
AGN-210961 Formulation 1, AGN-210961 Formulation 2, AGN-210961 Formulation 3, AGN-210961 Formulation 4, AGN-210961 Formulation 5, AGN-210961 Formulation 6, AGN-210961 Formulation 7, bimatoprost ophthalmic solution 0.03%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Sep 11, 2026, 8:31 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT01291108
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
AGN-210669, bimatoprost, bimatoprost vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Sep 11, 2026, 8:31 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues

NCT00539526
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost 0.03%, travoprost 0.004%, latanoprost 0.005% eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 11, 2026, 8:31 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension

NCT00541242
View directory record Official record
Conditions
Ocular Hypertension, Glaucoma
Interventions
bimatoprost 0.03% eye drops, latanoprost 0.005% eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2011 · Synced Sep 11, 2026, 8:31 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00651859
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Bimatoprost 0.01% Ophthalmic Solution, Bimatoprost 0.03% Ophthalmic Solution, Bimatoprost Vehicle Ophthalmic Solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
20 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Sep 11, 2026, 8:31 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss

NCT01325350
View directory record Official record
Conditions
Alopecia, Baldness
Interventions
bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C, bimatoprost vehicle solution, minoxidil 2% solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 59 Years · Female only
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Sep 11, 2026, 8:31 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence

NCT00693420
View directory record Official record
Conditions
Eyelashes
Interventions
Bimatoprost 0.03% sterile solution, vehicle sterile solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Sep 11, 2026, 8:31 AM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study of the Bimatoprost Ocular Insert

NCT02358369
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost, Timolol 0.5%, Placebo Ocular Insert, Placebo Eye Drops
Drug · Device
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
10
States / cities
Fayetteville, Arkansas • Artesia, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Sep 11, 2026, 8:31 AM EDT
Completed Phase 4 Interventional Results available

SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)

NCT02419508
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Brinz/brim vehicle, Prostaglandin analogue
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Sep 11, 2026, 8:31 AM EDT
Completed Phase 4 Interventional Results available

Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

NCT00440011
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
bimatoprost 0.03% eye drops, travoprost 0.004% eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Sep 11, 2026, 8:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT00809848
View directory record Official record
Conditions
Ocular Hypertension, Glaucoma
Interventions
AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, AGN-210669 ophthalmic solution, 0.025%, bimatoprost ophthalmic solution 0.03%, AGN-210669 vehicle ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2013 · Synced Sep 11, 2026, 8:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension

NCT01157364
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
bimatoprost 20 µg generation 2, bimatoprost 15 µg generation 2, bimatoprost 10 µg generation 2, bimatoprost 6 µg generation 2, bimatoprost 15 µg generation 1, bimatoprost 10 µg generation 1, bimatoprost 0.03%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
36
States / cities
Artesia, California • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Sep 11, 2026, 8:31 AM EDT
Recruiting Phase 3 Interventional

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

NCT05401357
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
9
States / cities
Newport Beach, California • Petaluma, California • New Smyrna Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Sep 11, 2026, 8:31 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension

NCT01863953
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Fixed-Combination Bimatoprost/Brimonidine, Bimatoprost Ophthalmic Solution 0.01%, Vehicle Ophthalmic Solution, Brimonidine Tartrate Ophthalmic Solution 0.2%
Drug
Lead sponsor
Allergan
Industry
Eligibility
40 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Sep 11, 2026, 8:31 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin

NCT00907426
View directory record Official record
Conditions
Hypotrichosis
Interventions
Bimatoprost 0.03% solution, Vehicle solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Sep 11, 2026, 8:31 AM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

NCT02676310
View directory record Official record
Conditions
Alopecia, Alopecia, Androgenetic, Baldness
Interventions
Bimatoprost
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Austin, Texas • College Station, Texas • Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Sep 11, 2026, 8:31 AM EDT